Phillip Furman currently serves as the President of the International Society for Antiviral Research (ISAR), where he leverages his extensive experience in antiviral drug discovery and development to advance the society's mission of promoting research and education in the field of infectious diseases. With a...
Phillip Furman currently serves as the President of the International Society for Antiviral Research (ISAR), where he leverages his extensive experience in antiviral drug discovery and development to advance the society's mission of promoting research and education in the field of infectious diseases. With a robust background that includes pivotal roles at Pharmasset, Inc. as Vice President of Biological Science and Triangle Pharmaceuticals as Chief Scientific Officer, Phillip has consistently demonstrated a commitment to innovation in the pharmaceutical industry. His leadership at ISAR focuses on fostering collaboration among researchers, clinicians, and industry stakeholders to accelerate the development of novel antiviral therapies.
Under Phillip's guidance, ISAR has initiated several key projects aimed at enhancing the understanding of viral pathogenesis and the immune response, which are critical for the development of effective antiviral interventions. His expertise in microbiology, immunology, and clinical trials positions him as a thought leader in the field, enabling him to contribute significantly to discussions on emerging infectious diseases and the challenges posed by viral resistance. Furthermore, Phillip's advisory roles with various pharmaceutical companies and venture capital firms underscore his strategic vision and ability to navigate the complexities of drug development.
As a passionate advocate for scientific advancement, Phillip is dedicated to mentoring the next generation of researchers and fostering an environment where innovative ideas can flourish. His commitment to education and collaboration within the antiviral research community is instrumental in driving progress and improving patient outcomes globally.
